Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Next Previous
Trial Profile

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pembrolizumab (Primary) ; Rinatabart sesutecan (Primary)
  • Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Male breast cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms GCT1184-01/PRO1184-001; RAINFOL-01
  • Sponsors ProfoundBio

Most Recent Events

  • 26 May 2026 Planned number of patients changed from 764 to 884.
  • 13 Apr 2026 According to a Genmab media release, Cara Mathews, M.D. and Associate Professor, Obstetrics and Gynecology at the Women and Infants Hospital, Brown University is an investigator in this study.
  • 13 Apr 2026 According to a Genmab media release, data from the combination therapy cohort D2 of this trial were presented during an oral session at the 2026 Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO) in San Juan, Puerto Rico.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top